Riverview Patients Join National Lawsuits Over GLP-1 Drug Vision Loss Claims

Dozens of personal injury lawsuits have been filed against the makers of popular GLP-1 medications Ozempic, Wegovy, and Mounjaro, alleging sudden vision loss. These lawsuits claim patients were not warned about the risk of nonarteritic anterior ischemic optic neuropathy (NAION), a condition that causes painless and sudden vision changes, typically in one eye.

The legal challenges are mounting, with nearly 1,000 lawsuits filed in New Jersey alone over the past year concerning these drugs and vision issues. Riverview residents using these medications may find themselves impacted by these developments, as the drugs reportedly lack NAION warning labels in the U.S., despite having them in other countries.

NAION occurs when there is insufficient blood flow to the eye, leading to rapid-onset vision changes. While there is currently no proven treatment for NAION, researchers are investigating a potential link to GLP-1 medications. A medical facility in Boston sent a safety alert in 2024 regarding a possible connection, though no study has yet proven the drugs caused the condition. NAION is rare and typically affects individuals over 50.

Both Novo Nordisk and Lilly, manufacturers of the drugs, have stated they take adverse event reports seriously and are defending against the lawsuits. Lilly emphasized patient safety as a top priority, while Novo Nordisk maintained the lawsuits are without merit. As legal proceedings continue, patients using these medications should consult their healthcare providers with any concerns.